Eli Lilly And Co (NYSE:LLY) was the target of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 103,663,031 shares, a growth of 193.9% from the February 15th total of 35,274,912 shares. Based on an average trading volume of 22,593,431 shares, the short-interest ratio is presently 4.6 days. Approximately 11.3% of the shares of the stock are sold short.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 4,000 shares of the company’s stock in a transaction dated Thursday, January 31st. The stock was sold at an average price of $120.00, for a total value of $480,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $127.01, for a total value of $127,010.00. The disclosure for this sale can be found here. Insiders have sold a total of 833,190 shares of company stock worth $102,388,102 in the last 90 days. 0.11% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of LLY. FDx Advisors Inc. raised its stake in shares of Eli Lilly And Co by 48.3% in the fourth quarter. FDx Advisors Inc. now owns 19,504 shares of the company’s stock worth $2,257,000 after purchasing an additional 6,356 shares during the last quarter. State of Alaska Department of Revenue raised its stake in shares of Eli Lilly And Co by 3.3% in the fourth quarter. State of Alaska Department of Revenue now owns 204,487 shares of the company’s stock worth $23,660,000 after purchasing an additional 6,474 shares during the last quarter. Waverton Investment Management Ltd raised its stake in shares of Eli Lilly And Co by 1.9% in the fourth quarter. Waverton Investment Management Ltd now owns 12,724 shares of the company’s stock worth $1,472,000 after purchasing an additional 238 shares during the last quarter. Sumitomo Life Insurance Co. raised its stake in shares of Eli Lilly And Co by 2.7% in the fourth quarter. Sumitomo Life Insurance Co. now owns 30,683 shares of the company’s stock worth $3,551,000 after purchasing an additional 800 shares during the last quarter. Finally, Pennsylvania Trust Co raised its stake in shares of Eli Lilly And Co by 46.4% in the fourth quarter. Pennsylvania Trust Co now owns 85,021 shares of the company’s stock worth $9,839,000 after purchasing an additional 26,947 shares during the last quarter. 77.00% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have commented on the company. Zacks Investment Research upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $121.00 price target on the stock in a research report on Wednesday, December 19th. JPMorgan Chase & Co. began coverage on Eli Lilly And Co in a research note on Tuesday, March 12th. They issued an “overweight” rating and a $140.00 price objective on the stock. Citigroup downgraded Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $115.00 price objective on the stock. in a research note on Monday, November 26th. BMO Capital Markets reissued a “buy” rating on shares of Eli Lilly And Co in a research note on Wednesday, December 19th. Finally, Morgan Stanley set a $116.00 price objective on Eli Lilly And Co and gave the company a “hold” rating in a research note on Thursday, December 20th. Eleven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Eli Lilly And Co has a consensus rating of “Buy” and a consensus target price of $113.06.

LLY stock opened at $123.94 on Friday. Eli Lilly And Co has a fifty-two week low of $74.51 and a fifty-two week high of $130.75. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.38 and a current ratio of 1.73. The company has a market cap of $128.33 billion, a P/E ratio of 22.33, a PEG ratio of 2.49 and a beta of 0.33.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.03). Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The firm had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. During the same period last year, the company posted $1.14 earnings per share. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, equities research analysts forecast that Eli Lilly And Co will post 5.62 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, March 8th. Investors of record on Friday, February 15th were paid a dividend of $0.645 per share. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.56. This represents a $2.58 dividend on an annualized basis and a yield of 2.08%. The ex-dividend date of this dividend was Thursday, February 14th. Eli Lilly And Co’s dividend payout ratio is 46.49%.

ILLEGAL ACTIVITY WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/eli-lilly-and-co-lly-short-interest-update/2896111.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Outstanding Shares and The Effect on Share Price

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.